Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bales Scientific FDA Warning Cites Website Promotion Of Unapproved Uses

This article was originally published in The Gray Sheet

Executive Summary

Bales Scientific's website disclaimer that its infrared-emitting pain management system is not approved to treat specific medical conditions is not likely to be deemed acceptable by the FDA, agency staffers maintain, because the site goes on to describe conditions for which the system might be used.

You may also be interested in...



CTI To Own Thermal Imaging Processor Outright Following Bales Acquisition

Computerized Thermal Imaging's acquisition of infrared imaging system manufacturer Bales Scientific includes Bales' thermal imaging processor, an adjunctive diagnostic tool that CTI already uses as part of its own thermal imaging system for breast cancer.

CTI To Own Thermal Imaging Processor Outright Following Bales Acquisition

Computerized Thermal Imaging's acquisition of infrared imaging system manufacturer Bales Scientific includes Bales' thermal imaging processor, an adjunctive diagnostic tool that CTI already uses as part of its own thermal imaging system for breast cancer.

Vysis Improperly Promoting AneuVysion Assay On Website - Warning Letter

Vysis, Inc.' s website improperly promotes the AneuVysion assay as a replacement for standard cytogenic tests to diagnose certain birth defects, FDA says in a Feb. 2 warning letter to the company.

Related Content

UsernamePublicRestriction

Register

MT013173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel